Tisotumab Vedotin: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01633-8
Abstract: Tisotumab vedotin (Tivdak™) is an antibody-drug conjugate comprising a fully human monoclonal antibody specific for tissue factor (TF-011) conjugated to monomethyl auristatin E (MMAE) that has been engineered to target tissue factor expressing tumours. Based… read more here.
Keywords: tisotumab vedotin; vedotin; first approval; vedotin first ... See more keywords
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-2962
Abstract: Purpose: Tissue factor (TF) is a potential target in cervical cancer, as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody–drug conjugate targeting TF, has demonstrated encouraging activity… read more here.
Keywords: metastatic cervical; cancer; tisotumab vedotin; recurrent metastatic ... See more keywords
A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Pharmacotherapy"
DOI: 10.1177/10600280221118370
Abstract: Objective: To evaluate the safety and efficacy of tisotumab vedotin-tftv (TV), a first-in-class vectorized anti-tissue factor (TF) antibody-drug conjugate (ADC), for the treatment of recurrent or metastatic cervical cancer. Data Sources: A literature search of… read more here.
Keywords: cervical cancer; cancer; metastatic cervical; recurrent metastatic ... See more keywords
A review of the novel tissue factor antibody–drug conjugate: Tisotumab vedotin
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221139775
Abstract: Objective To review and compare the pharmacology, efficacy, and safety of the novel tissue factor antibody–drug conjugate, tisotumab vedotin Data sources Literature search was performed through PubMed MEDLINE, Google Scholar, ClinicalTrials.gov, and the Food and… read more here.
Keywords: novel tissue; tissue factor; vedotin; drug ... See more keywords
Tisotumab vedotin; First FDA Approved Antibody-drug Conjugate for Cervical Cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Anti-cancer agents in medicinal chemistry"
DOI: 10.2174/1871520622666220421095240
Abstract: read more here.
Keywords: cancer; approved antibody; vedotin first; tisotumab vedotin ... See more keywords